Chadi Nabhan, hematologist and medical oncologist, Chief Medical Officer and Head of Strategy at Ryght, shared a post on LinkedIn:
“Just as we all head to the annual ASCO26 meeting in Chicago, I am proud to share that the American Society of Clinical Oncology (ASCO) and Ryght AI are collaborating to accelerate site selection for an important breast cancer clinical trial.
ASCO is using Ryght’s AI Site Twin platform to identify and activate research sites for the CDK4/6 Inhibitor Dosing Knowledge (CDK) Study – evaluating optimal starting doses of CDK4/6 inhibitors in patients with metastatic breast cancer, with a specific focus on older adults who are often underrepresented in these trials.
The future of clinical research will depend not only on discovering new therapies, but also on improving how we operationalize and deliver trials at scale. At Ryght AI we are optimizing site selection, accelerating feasibility, and improving site activation. This will remove many bottlenecks in clinical trial operations. Thank you to ASCO, Julie Gralow, and team for entrusting us and our technology in this important endeovor.”
Other articles about Chadi Nabhan on OncoDaily.